Related patents keep emerging, and compounds that have entered the clinical trial stage have been reported [153, 154].Some literature indicates that in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), the BRD4 degrader dBET6 is a more effective anti - cancer drug than the traditional BRD4 inhibitor JQ1, and it can targetedly inhibit some signal pathways that induce tumor drug resistance [155]. This evidence concerns the gene BRD4 and neoplasm.